Results 121 to 130 of about 8,557 (171)

A retrospective, multinational, cross-sectional survey of real-world outcomes for patients with axial spondyloarthritis receiving subcutaneous infliximab

BMC Rheumatology
Background CT-P13 SC, a new subcutaneous (SC) formulation of biosimilar infliximab (IFX), was approved by the European Medicines Agency in 2020 for the treatment of radiographic axial spondyloarthritis (axSpA) in adult patients.
Xenofon Baraliakos, Ye Eun Lee, Soyeon Park, Young Nam Lee, Isabel Truman, Molly Edwards, Emily Quiñones, Raj Sengupta   +7 more
doaj   +1 more source

CT-P13 biosimilar is non-inferior to infliximab [PDF]

Nature Reviews Gastroenterology & Hepatology, 2019
openaire   +2 more sources

Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries. [PDF]

BMC Health Serv Res, 2022
Yoo HK, Byun HG, Caprioli F, Fumery M, Peyrin-Biroulet L, Sreedhar S, Potter J, Jang M.   +7 more
europepmc   +1 more source

The reference infliximab medicine and biosimilar CT-P13 induce a similar immune response in inflammatory bowel disease patients [PDF]

, 2018
Tese de mestrado, Ciências Biofarmacêuticas, Universidade de Lisboa, Faculdade de Farmácia, 2018The use of therapeutic mAbs as the anti-TNFa agents has been known not to cure, but treat auto-immune diseases such as the inflammatory bowel diseases (IBD ...
Santos, Miguel Roque
core  

Impact of Infliximab Biosimilar CT-P13 Dose and Infusion Interval on Real-World Drug Survival and Effectiveness in Patients with Ankylosing Spondylitis. [PDF]

J Clin Med, 2021
Lee SS, Kim TH, Park W, Song YW, Suh CH, Kim SK, Yoo DH.   +6 more
europepmc   +1 more source

A Look Beyond the Biosimilarity of the Molecules. [PDF]

, 2015
Michetti, P.
core   +1 more source

Post-marketing analysis for biosimilar CT-P13 in inflammatory bowel disease compared with external data of originator infliximab in Japan. [PDF]

J Gastroenterol Hepatol, 2021
Sagami S, Nishikawa K, Yamada F, Suzuki Y, Watanabe M, Hibi T.   +5 more
europepmc   +1 more source

Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial. [PDF]

Rheumatology (Oxford), 2021
Westhovens R, Wiland P, Zawadzki M, Ivanova D, Kasay AB, El-Khouri EC, Balázs É, Shevchuk S, Eliseeva L, Stanislavchuk M, Yatsyshyn R, Hrycaj P, Jaworski J, Zhdan V, Trefler J, Shesternya P, Lee SJ, Kim SH, Suh JH, Lee SG, Han NR, Yoo DH.   +21 more
europepmc   +1 more source

Real-life drug persistence in patients with rheumatic diseases treated with CT-P13: a prospective observational cohort study (PERSIST). [PDF]

Rheumatol Adv Pract, 2021
Taylor PC, Christensen R, Moosavi S, Selema P, Guilatco R, Fowler H, Mueller M, Liau KF, Haraoui B.   +8 more
europepmc   +1 more source

Exploring the Reasons Behind the Substantial Discontinuation Rate Among Patients Taking CT-P13 in a Large Tertiary Hospital in Western Switzerland: A Retrospective Cohort Study Using Routinely Collected Medical Data. [PDF]

Drugs Real World Outcomes, 2022
Krstic M, Devaud JC, Marti J, Sadeghipour F.   +3 more
europepmc   +1 more source